Blood Cancer Talks

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:

1. ASH choosing wisely:
2. International Consensus Classification (ICC):
3. WHO classification 2022:
4. IPSS-M:
5. Romiplostim in MDS:
6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
7. Luspatercept in MDS:
8. Lenalidomide in MDS:
9.Iron chelation therapy in MDS:


What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk